Post-Finasteride Syndrome Update: Point/Counterpoint

This review examines the contentious issue of post-finasteride syndrome linked to 5-alpha reductase inhibitors and reports mixed findings on its sexual, physical, and psychological effects; the authors call for more rigorous studies.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

This study analyzed 3,295 cases from the FDA Adverse Event Reporting System to describe demographics and reporting trends of post-finasteride syndrome, finding that most reports came from patients rather than health professionals.